Merck & Co Inc (NYSE:MRK)
$ 130.06 -0.17 (-0.13%) Market Cap: 329.42 Bil Enterprise Value: 358.02 Bil PE Ratio: 144.51 PB Ratio: 8.16 GF Score: 88/100

Merck & Co Inc at Guggenheim Biopharma's Next Decade Virtual Conference Transcript

Jun 22, 2021 / 01:00PM GMT
Release Date Price: $76.19 (-0.73%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

Okay. Good morning, everybody. Hopefully, you can -- you hear me okay. Thanks very much for joining us for this 60-minute discussion with Merck's Executive Vice President and President of Merck Research Laboratories, Dr. Dean Li.

I'm Seamus Fernandez, one of the biopharma teams' senior therapeutic analyst here at Guggenheim. I'm really pleased that we've got Dr. Li here to join us as part of our new Guggenheim strategy series, which focuses exclusively on the innovation and strategies that biopharma companies are employing to benefit patients and drive growth for many years to come.

Dr. Li, frankly, I can't wait to discuss Merck's efforts and strategy to continue driving growth in the next decade and beyond. But before we do that, I just want to provide a little background and context for the discussion. As many of you know, Dr. Li serves as Executive Vice President, President of Merck Research Laboratories. He leads companies -- the company's worldwide human vaccines

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot